Why the study?
Does rivaroxaban reduce hospital length of stay compared to warfarin in adult patients hospitalized for non-valvular atrial fibrillation?
Does rivaroxaban reduce hospital length of stay compared to warfarin in adult patients hospitalized for non-valvular atrial fibrillation?
Rivaroxaban use is associated with a significantly shorter hospital length of stay compared to warfarin among patients hospitalized for non-valvular atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
May support shorter LOS with rivaroxaban in NVAF; leaves open causal benefit pending randomized confirmation.
Laliberté et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: